Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno‐Safety Technical Committee (ITC)Mineo Matsumoto, Jean G. Sathish, Cris Kampershroer et al.|Clinical Pharmacology & Therapeutics|2024Cited by 15
FIH dose selection beyond MABEL: Optimizing phase 1 clinical trial starting dose whilst protecting patient safetyMineo Matsumoto, Jean Sathish, J.Ryan Polli et al.|Regulatory Toxicology and Pharmacology|2026Cited by 0